Evaluation of FDY-5301 in Major Trauma Patients in ICU

Overview

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)

Full Title of Study: “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Intravenous FDY-5301 for the Prevention and Treatment of ICU Acquired Weakness in Major Trauma Patients.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: April 30, 2023

Detailed Description

The purpose of the trial is to evaluate the efficacy, safety, and PK of FDY-5301 compared to placebo in trauma ICU patients at risk of ICUAW. Muscle wasting occurs rapidly after major trauma and is often associated with multi-organ failure lasting from a few weeks to a long term disability. It is believed that FDY-5301 may help prevent or treat muscle weakness and organ dysfunction in major trauma patients. Approximately 252 subjects will be randomized (1:1:1) to receive up to 7 daily bolus IV doses of FDY-5301 at 1 mg/kg or 2 mg/kg, or volume-matched placebo. To ensure equal representation in each group, the randomization will be stratified by the presence or absence of any pelvic or lower limb fractures. All subjects who satisfy the eligibility criteria will be randomly allocated to one of three treatment groups (FDY-5301 low dose, FDY-5301 high dose, or placebo). All subjects will be followed for 6 months. This study will be conducted globally.

Interventions

  • Drug: FDY-5301
    • FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
  • Other: Placebo
    • Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.

Arms, Groups and Cohorts

  • Experimental: Experimental: FDY-5301 Low Dose
    • FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject’s body weight (estimated or actual) determined at screening.
  • Experimental: Experimental: FDY-5301 High Dose
    • FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject’s body weight (estimated or actual) determined at screening.
  • Placebo Comparator: Placebo
    • Placebo will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject’s body weight (estimated or actual) determined at screening. Other Names: Saline

Clinical Trial Outcome Measures

Primary Measures

  • Chelsea Critical Care Physical Assessment Tool
    • Time Frame: Day 10 or hospital discharge
    • CPAx total score at Day 10, or hospital discharge, whichever occurs first
  • Organ Dysfunction Total Time to Recovery
    • Time Frame: Hospital stay through Day 28
    • Organ dysfunction total time to recovery (TTR) until Day 28

Secondary Measures

  • Medical Research Council Sum Score
    • Time Frame: Day 28, or hospital discharge, whichever occurs first
    • MRC-SS at Day 28, or hospital discharge, whichever occurs first
  • Worst Sequential Organ Failure Assessment (SOFA) score
    • Time Frame: ICU hospital stay until Day 28 or ICU discharge if earlier
    • Worst Sequential Organ Failure Assessment (SOFA) score during ICU stay
  • Overall Survival at Day 28
    • Time Frame: Day 28
    • Overall survival

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18-75 years 2. Major trauma defined as: 1. thoracic and/or abdominal and/or pelvic injury 2. necessitating admission to ICU with ventilation anticipated for at least 24 hrs 3. hemorrhagic shock defined as systolic blood pressure (SBP) <90 mmHG requiring blood transfusion or base deficit of at least 6mEq/L pre-hospital arrival or within one hour after hospital arrival 3. IRB/IEC-approved consent obtained within 48 hours of first hospital arrival time (i.e., in case of transfers, use time of arrival to first hospital immediately post injury) Exclusion Criteria:

1. Likely to die within 48 hrs from time of screening 2. Any neurological condition that is perceived at the time of hospital admission as an immediate threat to life or incompatible with good functional recovery and where early limitation or withdrawal of therapy is being considered. For example: a. Computed tomography imaging showing evidence of traumatic brain injury (TBI), combined with best representative Glasgow Coma Score (GCS) Motor Score of ≤4 at approximately 24 hrs post injury 3. Evidence of nonreversible spinal cord injury 4. Bilateral femoral fractures 5. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative serum pregnancy test prior to randomization. 6. Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization 7. Known allergy to iodine 8. Chronic renal disease requiring dialysis 9. Body mass index (BMI) >40 kg/m2 or <16 kg/m2 10. Body weight (BW) >140 kg (or >309 lb) 11. History or presence of debilitating neurologic or other neuromuscular disease (e.g., spina bifida, amyotrophic lateral sclerosis, multiple sclerosis) at time of randomization 12. Current metastatic cancer 13. Solid organ transplant recipient 14. Evidence of pre-existing sarcopenia defined as having a pre-trauma Clinical Frailty Score (CFS) of ≥5 or based on clinical judgement (e.g. frail by appearance, cachexia, etc.) 15. Use of systemic corticosteroids, immunomodulators, or oncologic chemotherapy within 6 months of randomization (inhaled and topical steroids are allowed) 16. Use of investigational drugs or devices within 30 days of randomization 17. Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Faraday Pharmaceuticals, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Christian Buhagiar, 206-492-5310, info@faradaypharma.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.